BioSpace News Archive

Despite the benefits of hiring foreign-born STEM employees, some companies avoid it largely due to unfamiliarity with the visa process, according to two recruitment experts.

The global CAR T-Cell Therapy Market is projected to reach USD 22.2 billion by 2032 up from USD 2.1 billion in 2023, at a CAGR of 30% from 2024-2032.

A recent market report published by nova one advisor, the global generic drugs market size was estimated at USD 465.19 billion in 2023 and is expected to be worth around USD 779.68 billion by 2033 with a CAGR of 5.3% from 2024 to 2033.

Products containing cannabidiol (CBD) and other legal hemp-derived THC alternatives have become increasingly popular and are appearing in stores and online throughout the United States.

Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the European Commission (EC) has approved a label extension for XTANDI™ (enzalutamide) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy.

Centessa Pharmaceuticals plc announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares, each representing one ordinary share, at a price to the public of $9.25 per ADS.

GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore.

Prime Medicine, Inc. today announced that the Company will present preclinical data highlighting the broad potential of its Prime Editing technology and supporting the advancement of its programs at the 3rd Annual LNP Formulation and Process Development Summit (Boston, April 29-May 2, 2024); the American Society of Cell & Gene Therapy 27th Annual Meeting.

Tome Biosciences, Inc. today announced that it will present preclinical data on its PGI technologies, integrase-mediated PGI (I-PGI) and ligase-mediated PGI (L-PGI), at ASGCT’s 27th Annual Meeting taking place May 7-11 in Baltimore, MD.